MRD results in ovarian samples and bone marrow
No. . | Type of ALL . | Molecular marker . | Ovarian cortex MRD . | Ovarian medulla MRD . | Bone marrow MRD . | Relapse Y/N . | Follow-up (d) . |
---|---|---|---|---|---|---|---|
1 | BCP-ALL | Ig/TCR | Positive <10−4 | Positive <10−4 | Undetectable | N | 1368 |
2 | BCP-ALL | Ig/TCR | Undetectable | Positive <10−4 | Undetectable | N | 1647 |
3 | BCP-ALL | Ig/TCR | Positive <10−4 | 3.10−4 | 10−3 | N | 84 |
4 | BCP-ALL | Ig/TCR | NA | Undetectable | Undetectable | N | 995 |
5 | BCP-ALL | Ig/TCR | Undetectable | Positive <10−4 | Positive <10−4 | N | 1126 |
6 | BCP-ALL | Ig/TCR | Undetectable | NA | Undetectable | N | 987 |
7 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 1096 |
8 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 49 |
9 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 26 |
10 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 686 |
11 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 477 |
12 | BCP-ALL | Ig/TCR | NA | Undetectable | Undetectable | N | 577 |
13 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Positive <10−4 | N | 344 |
14 | BCP-ALL | Ig/TCR | Undetectable | NA | Undetectable | N | 2136 |
15 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | NA | N | 400 |
16 | BCP-ALL | KMT2A-AFF1 | Undetectable | Undetectable | Positive <10−4 | Y | 520 |
17 | BCP-ALL | KMT2A-AFF1 | Undetectable | Undetectable | Undetectable | N | 245 |
18 | BCP-ALL | KMT2A-USP2 | NA | Positive <10−4 | Undetectable | N | 1105 |
19 | Ph+ ALL | BCR-ABL1 | Undetectable* | NA | 0.0011% | N | 1862 |
Ig/TCR | Undetectable | ||||||
20 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable | 0.00076% | N | 408 |
Ig/TCR | Positive <10−4 | Undetectable | |||||
21 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable* | 0.11% | N | 9 |
Ig/TCR | Undetectable | ||||||
22 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable* | 0.85% | N | 427 |
Ig/TCR | NA | ||||||
23 | Ph+ ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 793 |
24 | Ph+ ALL | BCR-ABL1 | 0.01% | 0.005% | Undetectable | N | 922 |
25 | T-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 548 |
26 | T-ALL | Ig/TCR | Undetectable | Undetectable | 2.10−4 | N | 1513 |
27 | T-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 610 |
28 | MPAL | Ig/TCR | 3.10−5 | Positive <10−4 | Positive <10−5 | Y | 635 |
29 | MPAL | KMT2A-AFF1 | Undetectable | Undetectable | Undetectable | Y | 692 |
30 | AUL | Ig/TCR | Undetectable | Positive <10−4 | Positive <10−4 | Y | 678 |
No. . | Type of ALL . | Molecular marker . | Ovarian cortex MRD . | Ovarian medulla MRD . | Bone marrow MRD . | Relapse Y/N . | Follow-up (d) . |
---|---|---|---|---|---|---|---|
1 | BCP-ALL | Ig/TCR | Positive <10−4 | Positive <10−4 | Undetectable | N | 1368 |
2 | BCP-ALL | Ig/TCR | Undetectable | Positive <10−4 | Undetectable | N | 1647 |
3 | BCP-ALL | Ig/TCR | Positive <10−4 | 3.10−4 | 10−3 | N | 84 |
4 | BCP-ALL | Ig/TCR | NA | Undetectable | Undetectable | N | 995 |
5 | BCP-ALL | Ig/TCR | Undetectable | Positive <10−4 | Positive <10−4 | N | 1126 |
6 | BCP-ALL | Ig/TCR | Undetectable | NA | Undetectable | N | 987 |
7 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 1096 |
8 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 49 |
9 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 26 |
10 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 686 |
11 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 477 |
12 | BCP-ALL | Ig/TCR | NA | Undetectable | Undetectable | N | 577 |
13 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | Positive <10−4 | N | 344 |
14 | BCP-ALL | Ig/TCR | Undetectable | NA | Undetectable | N | 2136 |
15 | BCP-ALL | Ig/TCR | Undetectable | Undetectable | NA | N | 400 |
16 | BCP-ALL | KMT2A-AFF1 | Undetectable | Undetectable | Positive <10−4 | Y | 520 |
17 | BCP-ALL | KMT2A-AFF1 | Undetectable | Undetectable | Undetectable | N | 245 |
18 | BCP-ALL | KMT2A-USP2 | NA | Positive <10−4 | Undetectable | N | 1105 |
19 | Ph+ ALL | BCR-ABL1 | Undetectable* | NA | 0.0011% | N | 1862 |
Ig/TCR | Undetectable | ||||||
20 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable | 0.00076% | N | 408 |
Ig/TCR | Positive <10−4 | Undetectable | |||||
21 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable* | 0.11% | N | 9 |
Ig/TCR | Undetectable | ||||||
22 | Ph+ ALL | BCR-ABL1 | Undetectable* | Undetectable* | 0.85% | N | 427 |
Ig/TCR | NA | ||||||
23 | Ph+ ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 793 |
24 | Ph+ ALL | BCR-ABL1 | 0.01% | 0.005% | Undetectable | N | 922 |
25 | T-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | Y | 548 |
26 | T-ALL | Ig/TCR | Undetectable | Undetectable | 2.10−4 | N | 1513 |
27 | T-ALL | Ig/TCR | Undetectable | Undetectable | Undetectable | N | 610 |
28 | MPAL | Ig/TCR | 3.10−5 | Positive <10−4 | Positive <10−5 | Y | 635 |
29 | MPAL | KMT2A-AFF1 | Undetectable | Undetectable | Undetectable | Y | 692 |
30 | AUL | Ig/TCR | Undetectable | Positive <10−4 | Positive <10−4 | Y | 678 |
Undetectable MRD means negative result obtained with a sensitivity of 10−4 or 10−5. BCR-ABL1 MRD results are expressed as BCR-ABL1/ABL1 transcripts ratio.
AUL, acute undifferentiated leukemia; BCP-ALL, B-cell precursor ALL; MPAL, mixed-phenotype acute leukemia; NA, not available; N, no; Ph+ ALL, ALL with Philadelphia chromosome; Y, yes.
MRD was undetectable in both BCR-ABL1 and Ig/TCR.